<DOC>
	<DOC>NCT02121847</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of cyclosporine 0.05% ophthalmic emulsion (RestasisÂ®) in patients with dry eye disease.</brief_summary>
	<brief_title>Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy</brief_title>
	<detailed_description />
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>History of dry eye in both eyes Willing to use eye drops for dry eye symptoms Anticipate wearing contact lenses during the study Laserassisted in situ keratomileusis (LASIK) surgery within the past 12 months Any ocular and/or lid surgeries within the past 6 months Cataract surgery in either eye Current or anticipated use of temporary punctal plugs during the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>